RxDoctor Payments Data

Gauri Dayal, MD

Family Medicine · League City, TXNPI 1538160635

Payments from drug & device makers

$536in general payments, 2019–2025

Across 27 payments — averaging $19.84 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$111
  • Amgen$90
  • Novo Nordisk$72
  • AstraZeneca$70
  • Takeda Pharmaceuticals U.S.A., Inc.$57
  • Nalpropion Pharmaceuticals LLC$31
  • plus $105 from 5 others

What the payments were for

  • Food & beverage$51496%
  • Education$214%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
AbbVie(2 entities)3$111
Amgen3$90
Novo Nordisk2$72
AstraZeneca5$70
Takeda Pharmaceuticals U.S.A., Inc.5$57
Nalpropion Pharmaceuticals LLC2$31
Pfizer2$29
Currax Pharmaceuticals LLC2$28
Lilly USA, LLC1$23
Teva Pharmaceuticals USA, Inc.1$13
GSK1$13

How this compares

$536 in reported general payments places this provider in the 50th percentile of 8,760 family medicine providers in Texas.

See all family medicine providers in Texas

Medicare billing

Part B allowed, 2024
$58,478
Medicare patients
94
Services billed
709

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide37$54,197
Rosuvastatin Calcium102$940
Armour ThyroidThyroid,pork19$902
SynthroidLevothyroxine Sodium24$846
Olmesartan Medoxomil36$665
Celecoxib39$650
Albuterol Sulfate HfaAlbuterol Sulfate14$538
Metformin Hcl ErMetformin Hcl32$418
Tamsulosin Hcl25$413
Metoprolol Succinate31$392
Bupropion XlBupropion Hcl12$367
Montelukast Sodium19$330
Levothyroxine Sodium62$323
Pantoprazole Sodium30$254
Escitalopram Oxalate19$236

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$72$54,19737 claims
AbbVieArmour Thyroid, Synthroid$111$1,74943 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 50th percentile of 8,760 family medicine providers in Texas.

Other family medicine in League City

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →